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ABSTRACT
This study reports the development and evaluation of an internally controlled real-time PCR targeting
the ospA gene for detection of Borrelia burgdorferi sensu stricto, Borrelia garinii, Borrelia afzelii and Borrelia
valaisiana. DNA was extracted using QIAamp DNA Blood Mini kit columns. DNA from 33 B. burgdorferi
sensu lato strains reacted in the assay, whereas no reactivity was observed with DNA from four relapsing
fever Borrelia spp., 11 unrelated spirochaetes, and 31 unrelated microorganisms. The quantitative
sensitivity of the assay was 1–10 fg of Borrelia DNA and one to five cultured Borrelia spirochaetes.
Cerebrospinal fluid (CSF) specimens from 70 patients sent for routine testing for neuroborreliosis, and
three CSF specimens containing B. garinii were also tested. Positive PCR results were obtained with all
three culture-confirmed neuroborreliosis specimens, five of ten neuroborreliosis specimens with specific
antibodies in CSF and pleocytosis, none of nine specimens from possible cases of early neuroborreliosis
(antibodies in serum, CSF pleocytosis, no antibodies in CSF), one of 15 specimens from patients with
active or past Lyme disease with neurological signs (antibodies in serum, no pleocytosis or antibodies in
CSF), and none of 36 specimens from patients without Lyme borreliosis (no antibodies in serum or CSF).
Overall, the real-time PCR assay enabled sensitive and specific detection of all B. burgdorferi sensu lato
species tested. The PCR had a sensitivity of 50% in patients with neuroborreliosis. The main diagnostic
role of the assay could be to confirm neuroborreliosis in patients for whom the diagnosis is doubtful.
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INTRODUCTION
Lyme borreliosis (LB) is the most common tick
(Ixodes)-borne human disease in North America
and Europe [1,2] and is caused by spirochaetes
belonging to the Borrelia burgdorferi sensu lato
genetic complex. In North America, Borrelia burg-
dorferi sensu stricto is the only causative genospe-
cies of LB, whereas LB in Europe is caused by
B. burgdorferi sensu stricto and B. burgdorferi sensu
lato species Borrelia afzelii and Borrelia garinii.
Reports of detection of Borrelia valaisiana DNA
from human skin, urine and cerebrospinal fluid
(CSF) samples [3–5] and results from serological
studies [6] suggest that B. valaisiana can probably
also cause LB, and possibly even neuroborreliosis.
Current microbiological diagnosis of neurobor-
reliosis using antibody detection in serum and
CSF is of limited efficacy because of differential
expression, cross-reactivity and intra-species vari-
ation [7]. In addition, previous studies have
described patients with positive PCR results, but
without detectable antibodies in CSF [8–14].
Detection of spirochaetes in CSF by culture or
PCR is desirable for confirmation of the clinical
diagnosis, and is most sensitive in patients with
acute disease (<2 weeks). However, culture is
slow, labour-intensive, expensive and insensitive
[15].
Molecular detection of Borrelia in CSF has been
used to provide early diagnosis of neuroborreli-
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osis. Different genes have been selected for use as
a target for detection, including the p66, 16S
rRNA, flagellin and 2H1 genes, the 30-kb circular
plasmid, and the plasmid-encoded ospA ⁄B gene
[8–14,16–27]. The highest sensitivities with CSF
have been found in studies using the ospA ⁄B
plasmid gene [14,18,19,23,24]. The ospA gene is a
fully sequenced plasmid gene specific for B. burg-
dorferi sensu lato species [1], including B. valaisiana
[28].
Low numbers of spirochaetes in CSF may not
be detected because of PCR inhibition. However,
real-time PCR enables accurate monitoring of
PCR inhibition by the use of internal controls.
Real-time PCR assays for Borrelia have been
developed for use with clinical specimens [27].
Clinical evaluation of real-time PCR with skin
biopsies from patients with erythema migrans
[29] showed good sensitivity (80%) in comparison
with conventional nested PCR (64%) or culture
(54%). In contrast, amplification of Borrelia DNA
from urine using real-time PCR was not success-
ful [30]. When a real-time PCR assay was used to
investigate 56 CSF samples from patients suspec-
ted of suffering from neuroborreliosis, only one
specimen was positive, implying low sensitivity
[26]. However, clinical data were not provided
and the specimens could have been obtained
mainly from patients with a different final diag-
nosis. Therefore, the clinical value of real-time
PCR for use with CSF samples has not been
established. The present study aimed to validate
an internally controlled, real-time PCR assay
targeting the ospA gene for detection of B. burg-
dorferi sensu stricto, B. afzelii, B. garinii and B. vala-
isiana in CSF specimens.
MATERIALS AND METHODS
Analytical sensitivity and specificity
Analytical sensitivity was determined using DNA extracted
from 33 cultured B. burgdorferi sensu lato control strains
described previously [31], comprising six B. burgdorferi sensu
stricto (B31, HB19, A44S, VS293, VS130, M16), 12 B. garinii
(A01C, A76S, A77C, A94S, PBi, VSDA, VSBM, VSBP, Ip89,
20047, NT29, M63), nine B. afzelii (PKo, VS461, A02S, A03S,
A17S, A26S, A51T, A63T, A67T), four B. valaisiana (VS116,
M19, M53, M57), one Borrelia japonica (H014) and one Borrelia
spielmani (A14S). Specificity was determined using: (i) DNA
extracted from four cultured relapsing fever (RF) Borrelia
control strains (Borrelia hermsii, Borrelia crocidurae A124B,
B. crocidurae A125B, Borrelia anserina) belonging to three
phylogenetic clusters [32] and cultured in modified Kelly’s
medium at 33C [31]; (ii) DNA extracted from unrelated
spirochaetes, namely a clinical specimen containing Treponema
pallidum, and ten Leptospira spp. belonging to different genetic
clusters [33], i.e., Leptospira interrogans serogroup Icterohaem-
orrhagiae serovar Lai (Lai), L. interrogans serogroup Ictero-
haemorrhagiae serovar Copenhageni (M20), L. interrogans
serogroup Canicola serovar Malaya (H6), Leptospira borgpe-
tersenii serogroup Serjoe serovar Hardjobovis (Lely 607),
Leptospira santarosai serogroup Shermani serovar Shermani
(1342K), Leptospira noguchii serogroup Panama serovar Panama
(CZ214K), Leptospura weilii serogroup Celledoni serovar Cell-
edoni (Celledoni), Leptospira kirschneri serogroup Autumnalis
serovar Bim (1051), Leptospira alexanderi serogroup Javanica
serovar Mengla (A85), and Leptospira meyeri serogroup Rana-
rum serovar Ranarum (ICF); and (iii) DNA extracted from the
following 31 unrelated microbial species and viruses: Entero-
coccus faecalis, Enterococcus faecium, Streptococcus pneumoniae,
Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus
salivarius, Staphylococcus aureus, Staphylococcus epidermidis, Neis-
seria meningitidis, Haemophilus influenzae, Moraxella catarrhalis,
Fusobacterium nucleatum, Pseudomonas aeruginosa, Escherichia
coli, Klebsiella pneumoniae, Enterobacter aerogenes, Acinetobacter
baumannii, Bacillus cereus, Listeria monocytogenes, Mycobacterium
tuberculosis, Mycobacterium avium, Mycobacterium abscessus,
Candida albicans, Cryptococcus neoformans, Toxoplasma gondii,
Mycoplasma pneumoniae, Chlamydia pneumoniae, herpes simplex
type 1, cytomegalovirus, Epstein–Barr virus and adenovirus.
The real-time PCR assay was also tested with a proficiency
panel that formed part of the 2003 Second External Quality
Assessment for the Molecular Detection of Borrelia (Belgian
National Committee for Molecular Diagnostics; http://
www.uia.ac.be/cmd/). The panel contained two negative
samples, five body fluids spiked with spirochaetes (two CSF
spiked with B. burgdorferi sensu stricto B31, two CSF spiked
with B. garinii N34, and a synovial fluid spiked with B. burg-
dorferi sensu stricto B31), a cultured dilution of B. burgdorferi
sensu stricto B31, and four DNA solutions (two weakly positive
and two strongly positive; two B. burgdorferi sensu stricto B31,
one B. garinii N34 and one B. afzelii ACA1).
Limiting dilutions
The quantitative sensitivity of the assay was determined
initially using limiting dilution series of known DNA concen-
trations of B. garinii A94S (1.30 lg ⁄ lL), B. afzelii A03S
(0.81 lg ⁄ lL) and B. burgdorferi sensu stricto A44S (1.25 lg ⁄ lL).
In a move towards clinical application, quantitative sensi-
tivity was also determined using limiting dilutions of cultured
B. garinii A87S (1.25 · 107 spirochaetes ⁄mL) spiked in normal
CSF samples. B. garinii A87S spirochaetes were cultured
freshly in Barbour–Stoenner–Kelly medium and quantified
using dark-field microscopy.
Clinical material
The real-time PCR was performed on clinical CSF specimens
sent to the laboratory for testing for neuroborreliosis (collected
between 1998 and 2004) and on three CSF specimens from
which B. garinii had been cultured (collected between 1987 and
1990). CSF specimens were categorised into five groups: (I)
culture-confirmed neuroborreliosis; (II) neuroborreliosis (anti-
bodies in CSF and pleocytosis, but culture not performed); (III)
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possible early neuroborreliosis (antibodies in serum, CSF
pleocytosis, no CSF antibodies); (IV) active or past LB and
neurological signs present (antibodies in serum, no CSF
pleocytosis or antibodies); and (V) no LB (no antibodies in
serum or CSF). Patients were assigned to groups II, III or IV on
the basis of anti-Borrelia IgG or IgM, or both classes of
antibody.
Clinical data for neuroborreliosis patients (antibodies in
CSF and pleocytosis, culture not performed) were collected.
The CSF samples were stored at )80C. Antibodies in CSF and
serum were determined by IgG and IgM flagellin-ELISA
(Dako, Glostrup, Denmark), using the procedure recommend-
ed by the manufacturer. CSF samples were tested in a 1:10
dilution. Antibodies in serum were confirmed by recombinant
immunoblot (Microgen, Martinsried, Germany). The criteria
for positivity recommended by the manufacturer were used,
implying that sera with IgM against OspC, or IgG against
p100, p39, OspC, p18, or against OspA as well as flagellin
fragments, were included as positives.
Nucleic acid isolation
Nucleic acid was extracted from the 33 B. burgdorferi sensu lato
and four RF Borrelia control strains by isopropanol precipita-
tion, following digestion with proteinase K and selective
precipitation with hexadecyltrimethyl ammonium bromide, as
described by Wilson [34], and was stored at )20C. DNA
concentrations were determined by spectrophotometry.
DNA from the CSF specimens spiked with B. garinii
spirochaetes, the proficiency panel specimens and the clinical
CSF specimens was extracted using a QIAamp DNA Blood
Mini kit (Qiagen, Hilden, Germany), following the manufac-
turer’s instructions. Additionally, from a number of speci-
mens, 500 lL was centrifuged (8000 g for 10 min) and the
pellets were resuspended in 100 lL of QIAamp elution buffer;
this was followed by extraction and elution as described
above. Purified nucleic acids were eluted in 100 lL of elution
buffer and stored at )20C. Sterile distilled water was used as a
negative control in each run.
Primers and probes for real-time PCR
Nucleotide sequence alignments of the ospA gene of 67
B. burgdorferi sensu lato species from GenBank were used to
design specific primers and a TaqMan probe using Beacon
Designer v.2.0 software (Premier Biosoft International, Palo
Alto, CA, USA). The 67 B. burgdorferi sensu lato species
included 16 B. burgdorferi sensu stricto, 31 B. garinii, five
B. afzelii, nine B. valaisiana and six other B. burgdorferi sensu
lato species. A BLAST search was performed to confirm the
specificity of the primer and probe sequences selected. The
forward primer, BORs 5¢-ATATTTATTGGGAATAGGTC-
TAATAT, and reverse primer, BORas 5¢-CTTTGTCTT-
TTTCTTTRCTTACAAG, amplified a 137-bp fragment from
the ospA gene. The TaqMan probe BOR-TQ-FAM AAGCA-
AAATGTTAGCAGCCTTGA was labelled at the 5¢-end with
the fluorescent reporter molecule 6-carboxy-fluorescein, and at
the 3¢-end with the quencher molecule 6-carboxytetramethyl-
rhodamine. Primer and probe nucleotide positions were 9–34
(BORs), 121–145 (BORas) and 52–74 (BOR-TQ-FAM) of the
ospA gene (GenBank accession number Y10841). The primers
were synthesised by Eurogentec (Seraing, Belgium) and the
probe by Biolegio (Malden, The Netherlands).
Borrelia ospA real-time PCR
The Borrelia ospA real-time PCR was optimised for magnesium
and primer concentrations. The assay was performed in 50-lL
reaction mixes containing 25 lL of HotStart Taq mastermix
(Qiagen, Hilden, Germany), 4.5 lM MgCl2, 0.3 lM each
primer, 0.3 lM probe and 10 lL of template. Amplification
comprised 15 min at 95C, followed by 50 cycles of 30 s at
95C, 30 s at 55C and 30 s at 72C. DNA extraction and
amplification was controlled by co-amplification and detection
of phocid herpes virus 1 (PhoHV-1) DNA spiked into the
samples as described previously [35]. The internal control was
co-amplified with the Borrelia real-time PCR by adding
0.05 lM each of PhoHV-1 primer and 0.5 lM PhoHV-1 probe.
All specimens were tested in duplicate for reproducibility, and
amplification products were evaluated by agarose gel electro-
phoresis. Amplification, detection and data analysis were
performed with an iCycler IQ real-time detection system (Bio-
Rad, Veenendaal, The Netherlands).
Conventional PCR
Use of a PCR targeting both Borrelia chromosomal DNA and
plasmid DNA has improved sensitivity with CSF samples in
some studies [19,23]. Therefore, an additional PCR was
developed that targeted the conserved Borrelia chromosomal
hbb gene using sequence alignments of 39 Borrelia strains
[36] from GenBank. The forward primer, BORs
5¢-GTTATTGARTTTAGATCTTTTGGTACA, and reverse pri-
mer, BORas 5¢-TTAACCTTTRATACCCCACACT, amplify a
168-bp fragment from the hbb gene. The assay was performed
in 50-lL reaction mixes containing 25 lL of HotStart Taq
mastermix kit, 3.5 lM MgCl2, 0.4 lM each primer and 20 lL
of template, using the same thermal profile as described
above for the ospA assay.
RESULTS
Sensitivity and specificity
The Borrelia ospA real-time PCR successfully
detected DNA extracted from all 33 B. burgdorferi
sensu lato strains, but did not amplify DNA
extracted from the four RF Borrelia strains. The
Borrelia real-time PCR was negative with DNA
extracted from unrelated spirochaetes (ten Lepto-
spira spp. and one clinical specimen containing
T. pallidum) and 31 unrelated microorganisms.
Ten-fold limiting dilution tests, using samples
with known concentrations of B. garinii, B. afzelii
or B. burgdorferi sensu stricto DNA, showed that
sensitivity, efficiency and correlation coefficiency
were not influenced by co-amplification of the
internal control (Table 1). The detection level of
the duplex assay was 1–10 fg for each Borrelia
DNA sample. In addition, ten-fold limiting
dilution tests of cultured B. garinii A87S
(1.25 · 107 spirochaetes ⁄mL) spiked into negative
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CSF samples showed that the quantitative sensi-
tivity of the duplex assay was one to five
spirochaetes, corresponding to the sensitivity
calculated on the basis of the DNA concentration
(one Borrelia spirochaete = 1.5 fg of DNA).
The duplex Borrelia real-time PCR detected all
ten positive samples in the Belgian proficiency
panel and was negative for the two negative
samples.
PCR results with clinical specimens
Results of Borrelia ospA real-time PCR with 73
clinical specimens, including three CSF specimens
from which B. garinii had been cultured, are
shown in Table 2. One culture-positive specimen
was initially negative in the real-time PCR
because of PCR inhibition, but was positive
following re-extraction. Initially, only three of
ten group II specimens were PCR-positive. Fol-
lowing centrifugation of CSF specimens from
groups II, III and IV when 500 lL was available,
Borrelia was additionally detected by real-time
PCR in two of four specimens from group II, none
of seven specimens from group III, and none of 13
specimens from group IV. Thus, centrifugation
increased the sensitivity of Borrelia detection by
real-time PCR in patients with neuroborreliosis
(Table 3), but not in the other patients. No
additional positive Borrelia results were obtained
when all clinical specimens were tested in dupli-
cate or following agarose gel electrophoresis of
amplification products from neuroborreliosis
specimens. No discrepant results were obtained
following duplicate testing. All positive CSF
Table 1. Cycle threshold values of single Borrelia real-
time PCR assays in comparison with the duplex Borrelia
PhoHV-1 real-time PCR for detection of Borrelia DNA
dilution series
Limiting dilution Borrelia DNA
Ct value
Borrelia PCR
Borrelia PhoHV-1
duplex PCR
Borrelia A44Sa (1250 mg ⁄L)
10)6 28.4 28.3
10)7 32.0 31.8
10)8 35.5 34.9
10)9 39.0 39.4
10)10 43.9 40.6
Negative control Negative Negative
aBorrelia burgdorferi sensu stricto A44S.
Ct, cycle threshold crossing-point; PhoHV-1, phocid herpes virus 1 (real-time PCR
internal control).
Table 2. Comparison of Borrelia real-time PCR results with other parameters for clinical cerebrospinal fluid (CSF)
specimens
Group Diagnosis
Neurological
symptoms Culture
CSF
antibodies
CSF
leukocytes
Serum
antibodies Total
PCR
+ –
I Neuroborreliosis, culture-positive + + + + + 3 3a 0
II Neuroborreliosis + ND + + + or – 10 5 5
III Possible early neuroborreliosis + ND – + + 9 0 9
IV Lyme disease with neurological signs + ND – – + 15 1 14
V No Lyme borreliosis + ND – – – 36 0 36
aOne specimen initially inhibited, positive after re-extraction.
Table 3. Characteristics and laboratory findings in cerebrospinal fluid (CSF) and blood for group II neuroborreliosis
patients
Patient no. Gender ⁄ age (years) Clinical manifestations
Blood CSF
IgM IgG IgM IgG
ospA PCR (Ct)
Cell count
(WBC/lL)100 lL 500 lL
1 F ⁄ 8 Left facial palsy; fatigue – – + + – NA 236
2 F ⁄ 6 Diplopia; abducens nerve paresis + + + + + (43.4)a NA 81
3 M ⁄ 62 Bilateral facial palsy – – + + + (45.0) NA 485
4 F ⁄ 44 Right facial palsy; headache; dizziness + + + + – + (39.5)a 474
5 M ⁄ 10 Left facial palsy + + – + – NA 77
6 M ⁄ 21 Right facial palsy; hearing ⁄ taste impaired + + + + – – 53
7 M ⁄ 34 Bilateral facial palsy; hearing ⁄ taste impaired – + + + – + (42.4) 240
8 F ⁄ 59 Abdominal wall paresis and pain + – + – – NA 89
9 M ⁄ 9 Right facial palsy + + + + + (43.1) NA 37
10 F ⁄ 63 Right facial palsy; headache + + + + – – 42
aPCR-positive for hbb gene.
Ct, cycle threshold crossing-point; WBC, white blood cell; NA, not available (insufficient amount of CSF).
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samples had cycle threshold crossing-point (Ct)
values > 38 in the real-time PCR, indicating a low
level of DNA in CSF samples (Table 3). Sensitivity
of the conventional hbb PCR with all clinical
specimens was lower, as Borrelia was only
detected in two neuroborreliosis patients
(Table 3) and none of the other specimens.
Clinical data
Clinical details of the ten patients, which included
four children (two male), with neuroborreliosis
are shown in Table 3. The mean age was 31.6
(range 6–63) years. All ten patients had Borrelia-
specific antibodies and pleocytosis in CSF. Seven
were diagnosed with Bell’s palsy, and one had
abdominal pain and paresis. Abdominal pain and
abdominal wall paresis have been described
rarely as a misleading presentation of neurobor-
reliosis because of thoracic radiculoneuropathy
[37]. Two neuroborreliosis patients, one with a
PCR-positive CSF, did not have Borrelia-specific
antibodies in serum. The IgM immunoblot reac-
tion in the same serum specimen from one of
these patients (aged 8 years) was intermediate
and no subsequent serum specimen was obtained,
while a convalescent-phase specimen obtained
2 weeks later from the other patient (a male aged
62 years) was positive, indicating slower antibody
formation in serum than in CSF.
Only one of 60 patients with no antibodies in
the CSF was positive by PCR. This patient was a
female aged 49 years, with LB and neurological
signs (group IV), who had been treated with
doxycycline for a tick bite and erythema migrans,
and had presented 4 months later with dizziness
and concentration problems. Since the CSF con-
tained no leukocytes or antibodies, no further
treatment was given. No clinical follow-up was
possible.
DISCUSSION
The quantitative analytical sensitivity of the inter-
nally controlled real-time PCR for the Borrelia ospA
gene (1–10 fg of Borrelia DNA or one to five
cultured Borrelia spirochaetes per reaction) was
similar to those of previously described assays for
B. burgdorferi sensu stricto [14,23,24] and B. burg-
dorferi sensu lato [19] that targeted the ospA ⁄B gene.
Borrelia DNA was isolated efficiently using QIA-
amp nucleic acid extraction columns [26], and the
sensitivity of the assay with clinical specimens
obtained from ten neuroborreliosis patients (group
II) was 50%. This sensitivity was similar to that of
previously described nested PCR (47%) and stand-
ard PCR (38%) assays targeting ospA [19,25],
thereby providing the first description of a sensi-
tive clinically relevant real-time PCR for detection
of B. burgdorferi sensu lato in CSF samples.
Numerous PCR assays have been described
previously for the detection of B. burgdorferi sensu
lato DNA in CSF, but the reported sensitivities
have varied from 12% to 100% [8–14,16–27]. These
results are difficult to interpret because of the use
of small sample sizes, the differences in selection
of clinical specimens, the testing of poorly defined
patient categories, the occasional use of insensitive
assays, and the frequent lack of an internal control
to monitor PCR inhibition. No internally con-
trolled Borrelia real-time PCR has been validated
previously for sensitive detection of European
B. burgdorferi sensu lato in CSF. The real-time PCR
format has the advantages, compared with con-
ventional and nested PCR, of increased speed and
automation, accurate monitoring of PCR inhibi-
tion in the same reaction, and a decreased risk of
false-positives because of the elimination of post-
PCR processing of amplification products. The
importance of monitoring PCR inhibition was
shown in the present study, and has also been
demonstrated previously [18]. A further advant-
age of using real-time Borrelia PCR to test CSF
samples from suspected neuroborreliosis patients
is the possibility of simultaneous testing for other
microorganisms (e.g., herpes simplex virus or
varicella-zoster virus) in the differential diagnosis
with the same extracted DNA sample.
PCR assays described previously for detection
of Borrelia in CSF often have very low sensitivity,
and it has been postulated that this is associated
with the presence of low numbers of Borrelia
spirochaetes in CSF [8,9,11,13,14,16,17,19,21,25,
26]. In the present study, high Ct values with
non-inhibitory CSF samples confirmed the pres-
ence of low levels of Borrelia DNA. Failure to
detect Borrelia DNA in CSF specimens from some
neuroborreliosis patients could also be caused by
DNA degradation during storage. Because of the
expected low sensitivity for Borrelia detection in
CSF, all specimens were tested in duplicate, but
no discrepant results were observed.
In studies reporting a high sensitivity for PCR
detection of Borrelia in CSF, samples have been
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centrifuged before DNA extraction [12,13,16,
18,19,24]. In the present study, centrifugation of
500 lL of CSF from neuroborreliosis patients
(group II) resulted in detection of Borrelia DNA
in two specimens that were previously negative.
Three negative specimens could not be centri-
fuged because of the low sample volume avail-
able. Thus, the sensitivity of the assay could have
been >50% if larger volumes of CSF had been
available for all specimens. Routine centrifugation
of ‡500 lL of CSF before DNA extraction is
therefore recommended to increase the number
of PCR-positive results.
Previous studies have suggested that the low
sensitivity of PCR assays for detection of Borrelia
in CSF could be associated with genetic variability
of the ospA gene [16,18–21]. The present study
designed primers based on nucleotide sequence
alignments of the ospA gene of 67 B. burgdorferi
sensu lato species from GenBank. Analytical sen-
sitivity testing with 33 B. burgdorferi sensu lato
strains, including B. valaisiana cluster I and II ospA
variants [28], demonstrated that the assay detect-
ed all the B. burgdorferi sensu stricto, B. afzelii,
B. garinii and B. valaisiana strains tested. An addi-
tional PCR targeting Borrelia chromosomal DNA,
as opposed to plasmid DNA, demonstrated
improved sensitivity in some studies [19,23], but
this was not the case for the newly developed
PCR targeting the hbb gene that was used in the
present study.
In the EU Concerted Action on Risk Assess-
ment in Lyme Borreliosis (EUCALB) guidelines,
an essential diagnostic criterion for neuroborrel-
iosis is intrathecal antibody synthesis [38]. How-
ever, antibody formation lags behind the
appearance of the pathogen in other infectious
diseases. Also, in early erythema migrans, Borrelia
spirochaetes can be cultured readily, but an
immune response is often absent. Therefore, it
can be hypothesised that spirochaetes could be
detected by PCR during early neuroborreliosis
without any detectable antibodies in CSF [8–14].
In the present study, only one patient was found
to have a positive PCR and negative CSF serology,
but no clinical follow-up was possible. It was
concluded that, at least in patients with antibodies
in serum, a positive PCR result with CSF in the
absence of CSF antibodies would be rare.
In summary, the internally controlled Borrelia
real-time PCR described in this report is a
sensitive and specific assay for detection of
Borrelia burgdorferi sensu lato DNA in CSF. Cen-
trifugation of specimens before QIAamp column
DNA extraction provides enhanced sensitivity.
Since even this highly sensitive PCR is positive in
only 50% of patients with neuroborreliosis, a
negative PCR does not rule out this diagnosis. The
Borrelia real-time PCR is rarely positive in the
absence of antibodies in CSF. Therefore, meas-
urement of Borrelia antibodies and leukocyte
counts in CSF remain the basis for diagnosis of
neuroborreliosis. PCR analysis could have a role
in confirming the diagnosis of cases with other-
wise normal CSF findings that have a high index
of suspicion using clinical criteria, or in patients
with positive CSF leukocytes or antibodies for
whom the diagnosis of neuroborreliosis is still
doubtful on clinical grounds.
ACKNOWLEDGEMENTS
We thank A. Oei and L. Spanjaard (University of Amsterdam,
Amsterdam, The Netherlands) for providing cultured Borrelia
burgdorferi sensu lato spirochaetes. DNA extracted from Lepto-
spira spp. was kindly provided by A. Ahmed and R. A.
Hartskeerl (Department of Biomedical Research, Royal Trop-
ical Institute, Amsterdam, The Netherlands). We also thank V.
Avesani (Belgian National Committee for Molecular Diagnos-
tics; http://www.uia.ac.be/cmd/) for providing the ‘2003
Second External Quality Assessment for the Molecular Detec-
tion of Borrelia’ proficiency panel. The clinical contribution of
P. H. Rothbarth (Rijnland Hospital, Leiderdorp, The Nether-
lands) is also gratefully acknowledged.
REFERENCES
1. Wang G, van Dam AP, Schwartz I, Dankert J. Molecular
typing of Borrelia burgdorferi sensu lato: taxonomic, epi-
demiological, and clinical implications. Clin Microbiol Rev
1999; 12: 633–653.
2. Steere AC. Lyme disease. N Engl J Med 2001; 345: 115–125.
3. Rijpkema SG, Tazelaar DJ, Molkenboer MJ et al. Detection
of Borrelia afzelii, Borrelia burgdorferi sensu stricto, Borrelia
garinii and group VS116 by PCR in skin biopsies of
patients with erythema migrans and acrodermatitis
chronica atrophicans. Clin Microbiol Infect 1997; 3:
109–116.
4. Schaarschmidt D, Oehme R, Kimmig P, Hesch RD, Eng-
lisch S. Detection and molecular typing of Borrelia burg-
dorferi sensu lato in Ixodes ricinus ticks and in different
patient samples from southwest Germany. Eur J Epidemiol
2001; 17: 1067–1074.
5. Diza E, Papa A, Vezyri E, Tsounis S, Milonas I, Antoniadis
A. Borrelia valaisiana in cerebrospinal fluid. Emerg Infect Dis
2004; 10: 1692–1693.
6. Ryffel K, Peter O, Rutti B, Suard A, Dayer E. Scored anti-
body reactivity determined by immunoblotting shows an
association between clinical manifestations and presence
of Borrelia burgdorferi sensu stricto, B. garinii, B. afzelii, and
Gooskens et al. Real-time PCR for detecting Borrelia in CSF 899
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 894–900
B. valaisiana in humans. J Clin Microbiol 1999; 37: 4086–
4092.
7. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP.
Diagnosis of lyme borreliosis. Clin Microbiol Rev 2005; 18:
484–509.
8. Huppertz HI, Schmidt H, Karch H. Detection of Borrelia
burgdorferi by nested polymerase chain reaction in cere-
brospinal fluid and urine of children with neuroborrelio-
sis. Eur J Pediatr 1993; 152: 414–417.
9. Amouriaux P, Assous M, Margarita D, Baranton G, Saint
Girons I. Polymerase chain reaction with the 30-kb circular
plasmid of Borrelia burgdorferi B31 as a target for detection
of the Lyme borreliosis agents in cerebrospinal fluid. Res
Microbiol 1993; 144: 211–219.
10. Lebech AM, Hansen K, Brandrup F, Clemmensen O,
Halkier-Sorensen L. Diagnostic value of PCR for detection
of Borrelia burgdorferi DNA in clinical specimens from pa-
tients with erythema migrans and Lyme neuroborreliosis.
Mol Diagn 2000; 5: 139–150.
11. Lebech AM, Hansen K, Rutledge BJ, Kolbert CP, Rys PN,
Persing DH. Diagnostic detection and direct genotyping of
Borrelia burgdorferi by polymerase chain reaction in cere-
brospinal fluid in Lyme neuroborreliosis. Mol Diagn 1998;
3: 131–141.
12. Jaulhac B, Nicolini P, Piemont Y, Monteil H. Detection of
Borrelia burgdorferi in cerebrospinal fluid of patients with
Lyme borreliosis. N Engl J Med 1991; 324: 1440.
13. Pachner AR, Delaney E. The polymerase chain reaction in
the diagnosis of Lyme neuroborreliosis. Ann Neurol 1993;
34: 544–550.
14. Keller TL, Halperin JJ, Whitman M. PCR detection of
Borrelia burgdorferi DNA in cerebrospinal fluid of Lyme
neuroborreliosis patients. Neurology 1992; 42: 32–42.
15. Karlsson M, Hovind-Hougen K, Svenungsson B, Stiern-
stedt G. Cultivation and characterization of spirochetes
from cerebrospinal fluid of patients with Lyme borreliosis.
J Clin Microbiol 1990; 28: 473–479.
16. Lebech AM, Hansen K. Detection of Borrelia burgdorferi
DNA in urine samples and cerebrospinal fluid samples
from patients with early and late Lyme neuroborreliosis
by polymerase chain reaction. J Clin Microbiol 1992; 30:
1646–1653.
17. Zbinden R, Goldenberger D, Lucchini GM, Altwegg M.
Comparison of two methods for detecting intrathecal
synthesis of Borrelia burgdorferi-specific antibodies and
PCR for diagnosis of Lyme neuroborreliosis. J Clin Micro-
biol 1994; 32: 1795–1798.
18. Debue M, Gautier P, Hackel C et al. Detection of Borrelia
burgdorferi in biological samples using the polymerase
chain reaction assay. Res Microbiol 1991; 142: 565–572.
19. Priem S, Rittig MG, Kamradt T, Burmester GR, Krause A.
An optimized PCR leads to rapid and highly sensitive
detection of Borrelia burgdorferi in patients with Lyme
borreliosis. J Clin Microbiol 1997; 35: 685–690.
20. Chmielewski T, Fiett J, Gniadkowski M, Tylewska-
Wierzbanowska S. Improvement in the laboratory
recognition of lyme borreliosis with the combination of
culture and PCR methods. Mol Diagn 2003; 7: 155–162.
21. Christen HJ, Eiffert H, Ohlenbusch A, Hanefeld F. Evalu-
ation of the polymerase chain reaction for the detection of
Borrelia burgdorferi in cerebrospinal fluid of children with
acute peripheral facial palsy. Eur J Pediatr 1995; 154: 374–
377.
22. Eiffert H, Ohlenbusch A, Christen HJ, Thomssen R,
Spielman A, Matuschka FR. Nondifferentiation between
Lyme disease spirochetes from vector ticks and human
cerebrospinal fluid. J Infect Dis 1995; 171: 476–479.
23. Luft BJ, Steinman CR, Neimark HC et al. Invasion of the
central nervous system by Borrelia burgdorferi in acute
disseminated infection. JAMA 1992; 267: 1364–1367.
24. Liebling MR, Nishio MJ, Rodriguez A, Sigal LH, Jin T,
Louie JS. The polymerase chain reaction for the detection
of Borrelia burgdorferi in human body fluids. Arthritis
Rheum 1993; 36: 665–675.
25. Nocton JJ, Bloom BJ, Rutledge BJ et al. Detection of Borrelia
burgdorferi DNA by polymerase chain reaction in cere-
brospinal fluid in Lyme neuroborreliosis. J Infect Dis 1996;
174: 623–627.
26. Schwaiger M, Peter O, Cassinotti P. Routine diagnosis of
Borrelia burgdorferi (sensu lato) infections using a real-time
PCR assay. Clin Microbiol Infect 2001; 7: 461–469.
27. Exner MM, Lewinski MA. Isolation and detection of Bor-
relia burgdorferi DNA from cerebral spinal fluid, synovial
fluid, blood, urine, and ticks using the Roche MagNA Pure
system and real-time PCR. Diagn Microbiol Infect Dis 2003;
46: 235–240.
28. Wang G, van Dam AP, Dankert J. Two distinct ospA genes
among Borrelia valaisiana strains. Res Microbiol 2000; 151:
325–331.
29. Liveris D, Wang G, Girao G et al. Quantitative detection of
Borrelia burgdorferi in 2-millimeter skin samples of ery-
thema migrans lesions: correlation of results with clinical
and laboratory findings. J Clin Microbiol 2002; 40: 1249–
1253.
30. Wagner EM, Schmidt BL, Bergmann AR, Derler AM,
Aberer E. Inability of one-step real-time PCR to detect
Borrelia burgdorferi DNA in urine. J Clin Microbiol 2004; 42:
938.
31. Wang G, van Dam AP, Spanjaard L, Dankert J. Molecular
typing of Borrelia burgdorferi sensu lato by randomly
amplified polymorphic DNA fingerprinting analysis.
J Clin Microbiol 1998; 36: 768–776.
32. Ras NM, Lascola B, Postic D et al. Phylogenesis of relap-
sing fever Borrelia spp. Int J Syst Bacteriol 1996; 46: 859–865.
33. Levett PN. Leptospirosis. Clin Microbiol Rev 2001; 14: 296–
326.
34. Wilson K. Preparation of genomic DNA from bacteria. In:
Ausubel FM, ed., Current protocols in molecular biology,
vol. 1. New York: Wiley, 1997; 2.4.1–2.4.5.
35. Templeton KE, Scheltinga SA, Graffelman AW et al.
Comparison and evaluation of real-time PCR, real-time
nucleic acid sequence based amplification, conventional
PCR, and serology for diagnosis of Mycoplasma pneumoni-
ae. J Clin Microbiol 2003; 41: 4366–4371.
36. Valsangiacomo C, Balmelli T, Piffaretti JC. A phylogenetic
analysis of Borrelia burgdorferi sensu lato based on
sequence information from the hbb gene, coding for a
histone-like protein. Int J Syst Bacteriol 1997; 47: 1–10.
37. Mormont E, Esselinckx W, De Ronde T, Hanson P,
Deltombe T, Laloux P. Abdominal wall weakness and
lumboabdominal pain revealing neuroborreliosis: a report
of three cases. Clin Rheumatol 2001; 20: 447–450.
38. Stanek G, O’Connell S, Cimmino M et al. European Union
Concerted Action on Risk Assessment in Lyme Borreliosis:
clinical case definitions for Lyme borreliosis. Wien Klin
Wochenschr 1996; 108: 741–747.
900 Clinical Microbiology and Infection, Volume 12 Number 9, September 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 894–900
